开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
RUSSIAN CENBANK deputy governor said the bank can, through "carefully calibrated" monetary policy, ensure inf returns to target by 2027.
2026-07-14
RUSSIAN CENBANK deputy governor said the bank can, through "carefully calibrated" monetary policy, ensure inf returns to target by 2027.
返回
其他消息
2026-07-14
China Customs said in 1H eastern China's imports and exports exceeded 20 trillion yuan, up 16.5% YoY and accounting for 78.8% of China's total foreign trade value. Western, central and northeastern regions' imports and exports rose 20.3%, 20.0% and 8.6% YoY, respectively.
China Customs said in 1H eastern China's imports and exports exceeded 20 trillion yuan, up 16.5% YoY and accounting for 78.8% of China's total foreign trade value. Western, central and northeastern regions' imports and exports rose 20.3%, 20.0% and 8.6% YoY, respectively.
2026-07-13
China's State Council issued the National Health 15th Five-Year Plan, committing full-chain support for innovative drugs and medical devices. It directs regulators to optimize review and approval of innovative and clinically urgent medicines and to establish a comprehensive clinical evaluation system to support clinical use. The plan calls for accelerated R&D and application of cell and gene therapies, next‑generation antibodies, new vaccines, nucleic‑acid drugs and radiopharmaceuticals, and for
China's State Council issued the National Health 15th Five-Year Plan, committing full-chain support for innovative drugs and medical devices. It directs regulators to optimize review and approval of innovative and clinically urgent medicines and to establish a comprehensive clinical evaluation system to support clinical use. The plan calls for accelerated R&D and application of cell and gene therapies, next‑generation antibodies, new vaccines, nucleic‑acid drugs and radiopharmaceuticals, and for strengthened emergency vaccine and drug R&D, production and deployment. It seeks to expand pediatric drug options, deepen medtech–clinical collaboration and boost R&D of core technologies, components and finished high‑end devices. The plan also promotes AI across the pharma and medtech value chain and instructs improvement of health‑insurance support mechanisms, including refinement of the innovative‑drug reimbursement/catalogue.
Chat with us
, powered by
LiveChat